NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy […]
Save Foods: Nitrousink Commenced Controlled Trial for the Reduction of Greenhouse Gas Emissions
Neve Yarak, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) — Save Foods, Inc. (NASDAQ: SVFD) (FSE:80W), an agri-food tech leader, announced […]
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing […]
Osisko Development Intercepts 443.64 G/T Gold Over 1.19 Meters in Underground Sampling at Trixie, Tintic Project
MONTREAL, Dec. 21, 2023 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) is […]
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share Following the close […]
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe […]
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
– MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked […]
Clene Provides Update on ALS Clinical Development Meeting With FDA
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its […]
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months […]
ARKO Corp. Appoints Robert Giammatteo as Chief Financial Officer
RICHMOND, Va., Dec. 21, 2023 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), a Fortune 500 company […]
